TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

Authors: Anne Månsson Kvarnhammar, Juha Punnonen, Enping Hong, Diana Reich, Karan Uppal, Kathy Bang, David B Rosen, Burkhardt Laufer, Thomas Knappe, Jens Jakob Karlsson, Yu-Chi Lee, Dhruv Thakar, Luis Alejandro Zúñiga, Simran Singh Sabharwal, Janne Damm Olling, Kristian Kjaergaard, Thomas Kurpiers, Meike Schnabel, Philipp Glock, Joachim Zettler, Mathias Krusch, Ana Bernhard, Stefan Heinig, Valentino Konjik, Thomas Wegge, Yvonne Hehn, Steffen Killian, Laura Viet, Josefine Runz, Frank Faltinger, Mohammad Tabrizi, Kristin Laura Abel, Vibeke Miller Breinholt, Stina M Singel, Kennett Sprogøe

Source: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://jitc.bmj.com/content/10/7/e004991.full; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/c5975468cd0f4febb405f737118e732f